Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Apyx Medical (APYX) EBITDA (2016 - 2025)

Historic EBITDA for Apyx Medical (APYX) over the last 15 years, with Q3 2025 value amounting to -$832000.0.

  • Apyx Medical's EBITDA rose 7711.14% to -$832000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.5 million, marking a year-over-year increase of 5594.03%. This contributed to the annual value of -$18.8 million for FY2024, which is 918.94% down from last year.
  • As of Q3 2025, Apyx Medical's EBITDA stood at -$832000.0, which was up 7711.14% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Apyx Medical's EBITDA ranged from a high of -$832000.0 in Q3 2025 and a low of -$6.6 million during Q1 2024
  • Over the past 5 years, Apyx Medical's median EBITDA value was -$4.6 million (recorded in 2023), while the average stood at -$4.2 million.
  • As far as peak fluctuations go, Apyx Medical's EBITDA soared by 7933.4% in 2023, and later plummeted by 34914.98% in 2024.
  • Over the past 5 years, Apyx Medical's EBITDA (Quarter) stood at -$1.7 million in 2021, then tumbled by 250.65% to -$5.9 million in 2022, then increased by 2.65% to -$5.8 million in 2023, then surged by 47.23% to -$3.0 million in 2024, then soared by 72.7% to -$832000.0 in 2025.
  • Its EBITDA stands at -$832000.0 for Q3 2025, versus -$2.6 million for Q2 2025 and -$3.1 million for Q1 2025.